Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Februar 2021 07:15 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
13. Februar 2021 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
10. Februar 2021 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology

HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
19. November 2020 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
13. November 2020 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports Third Quarter 2020 Financial Results

HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
06. November 2020 08:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
22. Oktober 2020 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

HOUSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
09. September 2020 08:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
14. August 2020 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports Second Quarter 2020 Financial Results

HOUSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
13. August 2020 07:00 ET | Quelle: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

HOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...

Vorherige Seite

Nächste Seite